Premium Nahrungsergänzungsmittel | artgerecht

Benign Prostatic Hyperplasia (BPH) – Causes and Treatment

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that commonly affects older men and can obstruct urinary flow.

Regular tips about health Regular tips about health

Things worth knowing about "Benign Prostatic Hyperplasia"

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that commonly affects older men and can obstruct urinary flow.

What is Benign Prostatic Hyperplasia?

Benign prostatic hyperplasia (BPH) is a non-cancerous, age-related enlargement of the prostate gland. The prostate is a walnut-sized gland located just below the bladder that surrounds the urethra. As the glandular tissue grows, it can compress the urethra, leading to difficulties with urination. BPH is one of the most common conditions affecting older men and becomes increasingly prevalent after the age of 50.

Causes

The exact causes of BPH are not fully understood. Key contributing factors include:

Hormonal changes: As men age, the balance between androgens (particularly testosterone and dihydrotestosterone) and estrogens shifts, promoting prostate tissue growth.
Aging: BPH occurs almost exclusively in older men, with risk increasing significantly after age 40.
Genetic predisposition: A family history of BPH increases the likelihood of developing the condition.
Lifestyle factors: Obesity, physical inactivity, and metabolic syndrome are discussed as contributing factors.

Symptoms

Symptoms of BPH result from the physical compression of the urethra and impaired bladder emptying. Common symptoms include:

Frequent urge to urinate, including at night (nocturia)
Weak or intermittent urine stream
Difficulty starting urination
Feeling of incomplete bladder emptying (residual urine)
Dribbling after urination
In severe cases: complete urinary retention (a medical emergency)

Diagnosis

BPH is diagnosed through a combination of assessments:

Medical history and symptom scoring: The International Prostate Symptom Score (IPSS) is a standardized questionnaire used to assess symptom severity.
Digital rectal examination (DRE): The physician palpates the prostate through the rectum to assess its size and consistency.
Ultrasound (sonography): Used to measure prostate volume and assess residual urine in the bladder.
Uroflowmetry: Measures urine flow rate to evaluate bladder emptying efficiency.
PSA test (Prostate-Specific Antigen): A blood test used to rule out prostate cancer.
Urinalysis: To exclude urinary tract infections or other conditions.

Treatment

Watchful Waiting

For men with mild symptoms and no complications, a watchful waiting approach may be appropriate. Lifestyle modifications such as reducing fluid intake in the evening, regular physical activity, and pelvic floor exercises can help manage symptoms.

Medication

Alpha-1 blockers (e.g., tamsulosin, alfuzosin): Relax the smooth muscle of the prostate and bladder neck, improving urine flow.
5-alpha reductase inhibitors (e.g., finasteride, dutasteride): Block the conversion of testosterone to dihydrotestosterone, reducing prostate volume over time.
Combination therapy: Both drug classes may be combined in more severe cases.
PDE-5 inhibitors (e.g., tadalafil): Used when BPH is accompanied by erectile dysfunction.

Surgical and Minimally Invasive Procedures

Transurethral resection of the prostate (TURP): The gold standard surgical treatment; excess prostate tissue is removed via the urethra.
Laser procedures (e.g., holmium laser enucleation of the prostate, HoLEP): Less invasive alternatives to TURP with reduced bleeding risk.
Open prostatectomy: Reserved for very large prostates; involves surgical removal of the enlarged tissue.

Complications

If left untreated, BPH can lead to serious complications, including:

Acute urinary retention (sudden inability to urinate)
Bladder stones
Urinary tract infections
Bladder dysfunction or overdistension
Kidney damage due to urinary backflow (hydronephrosis)

References

European Association of Urology (EAU): EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), 2023.
Oelke M. et al. - EAU Guidelines on the Treatment and Follow-up of Non-Neurogenic Male Lower Urinary Tract Symptoms. European Urology, 2013.
Roehrborn CG. - Benign Prostatic Hyperplasia: An Overview. Reviews in Urology, 2005; 7 (Suppl 9): S3-S14.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.